Decades after cisplatin's approval, platinum-based chemotherapy continues to anchor treatment regimens across tumor types, new research finds.
|Articles|February 10, 2022
Daily Medication Pearl: Diroximel Fumarate (Vumerity)
Author(s)Saro Arakelians, PharmD
Diroximel fumarate (Vumerity) is indicated for the treatment of relapsing forms of multiple sclerosis.
Advertisement
Medication Pearl of the Day: Diroximel fumarate (Vumerity)
Indication: Diroximel fumarate (Vumerity)is indicated for the treatment of relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
Insight:
- Dosing: Starting dose 231 mg twice a day, orally, for 7 days. Maintenance dose after 7 days 462 mg administered as two 231 mg capsules twice a day, orally.
- Dosage forms: Delayed-release capsules 231 mg.
- Adverse events: Most common adverse reactions for dimethyl fumarate were flushing, abdominal pain, diarrhea, and nausea.
- Mechanism of action: MMF, the active metabolite of diroximel fumarate, has been shown to activate the nuclear factor (erythroid-derived 2)-like 2 (Nrf2) pathways in vitro and in vivo in animals and humans. The Nrf2 pathway is involved in the cellular response to oxidative stress. MMF has been identified as a nicotinic acid receptor agonist in vitro.
- Manufacturer: Biogen
Sources:
Advertisement
Related to this article
FDA clears tiratricol for MCT8 deficiency, lowering dangerous T3 and outlining dosing, lab testing, and pharmacy access.
AI-driven coding fuels specialty EHRs and telehealth tools, making ePrescribing faster, tailored, and affordable while shifting focus to workflow and compliance.
Approval spans early and levodopa-treated disease; a 6-week titration and CYP3A interactions put pharmacists at the center of starting therapy.
The once-daily tablet is the third approved treatment for fibrodysplasia ossificans progressiva (FOP), with CYP3A4 and metformin interaction guidance.
BRUIN CLL-313 showed significantly longer progression-free survival vs bendamustine plus rituximab, bringing a noncovalent BTK inhibitor to first-line care.
A behavioral walking program matched supervised aerobic training for improving asthma control in a randomized trial of physically inactive adults.
Phase 2b data from EASD 2026 show the amylin-incretin combination also cut HbA1c by up to 2.9% in adults with obesity or overweight and type 2 diabetes.
Advertisement
Advertisement
Trending on Pharmacy Times
1
What the 2025-2030 Dietary Guidelines Mean for Heart Health
2
Why Lp(a) Testing Lagged Behind LDL Cholesterol Screening
3
EloraTZP Delivers Up to 23.3% Weight Loss in Adults With Obesity and T2D
4
FDA Approves Pirtobrutinib for Previously Untreated CLL/SLL
5